News | mRNA Therapy May Offer a New Approach to Genetic Male Infertility: Mouse Study Restores Sperm Production
A new study found that targeted delivery of messenger RNA (mRNA) to specific testicular cells restored sperm production in mice with genetic infertility and enabled them to produce healthy offspring. The finding opens a new research direction for future treatments targeting genetic male infertility.
The research was led by researchers at Kyoto University in Japan and published in Stem Cell Reports on March 5, 2026.
Male Factors Account for Nearly Half of Infertility Cases
The World Health Organization estimates that about 10% of couples worldwide experience infertility, with male factors involved in approximately half of cases. Many cases of male infertility are associated with genetic defects that disrupt normal sperm production.
To explore a solution, the Kyoto University team developed targeted mRNA delivery technology intended to restore sperm production by temporarily supplying key genetic instructions rather than directly modifying the genome.
Team leader Professor Takashi Shinohara said mRNA is a short-lived molecule that carries genetic instructions and directs cells to produce specific proteins, allowing it to have a therapeutic effect without permanently altering cellular DNA.
Injecting mRNA Directly into Testicular Cells
In the experiment, researchers injected mRNA encoding specific genetic information directly into the testes of mice. The team first confirmed that the method successfully delivered the genetic instructions to key cell types, including:
Germ cells that produce sperm
Support cells that aid sperm development (Sertoli cells)
The researchers then used the technology to test whether it could restore fertility in mice with a genetic defect. The mice had a defect in their support cells that blocked sperm production. Similar defects in humans are also associated with male infertility and certain testicular disorders.
Brief Expression Restores Sperm Production
The injected mRNA remained active in the body for only about two days, but this brief expression was sufficient to restart spermatogenesis in the mice.
After treatment, the genetically infertile mice, which had been unable to produce sperm, began producing sperm again.
More importantly, sperm retrieved from these mice were used in in vitro fertilization experiments. When injected into mouse oocytes, the sperm successfully produced healthy offspring.
The result shows that mRNA delivery can restore sperm production and generate functional sperm capable of reproduction.
A Potential New Strategy for Treating Male Infertility
The researchers said the study is the first to demonstrate that mRNA delivery can correct a specific genetic defect causing male infertility.
Compared with gene editing, this approach has the advantage of being temporary and not permanently altering cellular DNA, potentially reducing risk.
However, the team emphasized that the findings are currently limited to animal models. Further animal studies are needed to assess the method’s safety and effectiveness before it can be considered for human clinical treatment.
If future research confirms its feasibility, targeted mRNA therapy could offer a new treatment option for some cases of male infertility caused by genetic defects.
News | mRNA Therapy May Offer a New Approach to Genetic Male Infertility: Mouse Study Restores Sperm Production
News | mRNA Therapy May Offer a New Approach to Genetic Male Infertility: Mouse Study Restores Sperm Production
A new study found that targeted delivery of messenger RNA (mRNA) to specific testicular cells restored sperm production in mice with genetic infertility and enabled them to produce healthy offspring. The finding opens a new research direction for future treatments targeting genetic male infertility.
The research was led by researchers at Kyoto University in Japan and published in Stem Cell Reports on March 5, 2026.
Male Factors Account for Nearly Half of Infertility Cases
The World Health Organization estimates that about 10% of couples worldwide experience infertility, with male factors involved in approximately half of cases. Many cases of male infertility are associated with genetic defects that disrupt normal sperm production.
To explore a solution, the Kyoto University team developed targeted mRNA delivery technology intended to restore sperm production by temporarily supplying key genetic instructions rather than directly modifying the genome.
Team leader Professor Takashi Shinohara said mRNA is a short-lived molecule that carries genetic instructions and directs cells to produce specific proteins, allowing it to have a therapeutic effect without permanently altering cellular DNA.
Injecting mRNA Directly into Testicular Cells
In the experiment, researchers injected mRNA encoding specific genetic information directly into the testes of mice. The team first confirmed that the method successfully delivered the genetic instructions to key cell types, including:
Germ cells that produce sperm
Support cells that aid sperm development (Sertoli cells)
The researchers then used the technology to test whether it could restore fertility in mice with a genetic defect. The mice had a defect in their support cells that blocked sperm production. Similar defects in humans are also associated with male infertility and certain testicular disorders.
Brief Expression Restores Sperm Production
The injected mRNA remained active in the body for only about two days, but this brief expression was sufficient to restart spermatogenesis in the mice.
After treatment, the genetically infertile mice, which had been unable to produce sperm, began producing sperm again.
More importantly, sperm retrieved from these mice were used in in vitro fertilization experiments. When injected into mouse oocytes, the sperm successfully produced healthy offspring.
The result shows that mRNA delivery can restore sperm production and generate functional sperm capable of reproduction.
A Potential New Strategy for Treating Male Infertility
The researchers said the study is the first to demonstrate that mRNA delivery can correct a specific genetic defect causing male infertility.
Compared with gene editing, this approach has the advantage of being temporary and not permanently altering cellular DNA, potentially reducing risk.
However, the team emphasized that the findings are currently limited to animal models. Further animal studies are needed to assess the method’s safety and effectiveness before it can be considered for human clinical treatment.
If future research confirms its feasibility, targeted mRNA therapy could offer a new treatment option for some cases of male infertility caused by genetic defects.
Story source:
Collected online